drugset / Trial / NCT06367283

Metformin Treatment of Patients with Hand Osteoarthritis

NCT06367283 ↗

Phase 3 Recruiting 150 enrolled Marius Henriksen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To compare metformin (2 g daily), or maximum tolerated dose, for 16 weeks with placebo as a treatment of hand osteoarthritis symptoms.

Timeline

Start
2024-06-03
Primary completion
2025-12
Completion
2026-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 1000 mg —

Indications